Fatal pulmonary fibrosis after rituximab administration
- 1 September 2009
- journal article
- case report
- Published by Springer Nature in Pediatric Nephrology
- Vol. 24 (9) , 1753-1755
Abstract
Idiopathic nephrotic syndrome is the most frequent glomerular disease during childhood. Although immunosuppressive agents are usually effective, some severe cases remain difficult to treat. We describe a female patient with secondary steroid-resistant nephrotic syndrome who no longer responded to conventional treatment. Owing to cyclosporine toxicity, rituximab was administered. Three days after treatment the patient’s clinical condition dramatically worsened and she developed acute respiratory distress. Despite all means used to treat her, she died 5 weeks after rituximab infusion. A pulmonary biopsy showed extensive fibrosis, while the alveolar epithelium was no longer visible.Keywords
This publication has 16 references indexed in Scilit:
- Rituximab in Patients with the Steroid-Resistant Nephrotic SyndromeNew England Journal of Medicine, 2007
- Rituximab‐induced interstitial lung diseaseAmerican Journal of Hematology, 2007
- Interstitial Pneumonitis and Alveolar Hemorrhage Complicating Use of RituximabRespiration, 2007
- Rituximab therapy for steroid-dependent minimal change nephrotic syndromePediatric Nephrology, 2006
- Resolution of Recurrent Focal Segmental Glomerulosclerosis Proteinuria after Rituximab TreatmentNew England Journal of Medicine, 2006
- Fatal Interstitial Pneumonitis Related to Rituximab-Containing RegimenClinical Lymphoma Myeloma and Leukemia, 2006
- Fatal Intra-Alveolar Hemorrhage After Rituximab in a Patient with non-Hodgkin LymphomaLeukemia & Lymphoma, 2004
- Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP)American Journal of Hematology, 2004
- Rituximab-Induced Acute Pulmonary FibrosisMayo Clinic Proceedings, 2004
- Interstitial Pneumonitis Related to Rituximab TherapyNew England Journal of Medicine, 2003